Uptrend Under Pressure 100
Institutional selling is building — 7 distribution days in the last 25 sessions. Severe risk · 100/100 · 7 distribution days (SPY) Oct 26 Full briefing →
View
Simple research view

CVS · CVS Health Corporation

$92.53 -1.01% Oct 26 close
Detected setup Trend Only · Setup Score 68/100

Stand aside — setup invalidated

Setup score 68, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about CVS

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$CVS

CVS Health Corporation

CVS Health Corporation is a large-cap Drugstore Chains company in the Retail Trade sector with a market cap of $118B.

Retail Trade Drugstore Chains stock Stage 2 · Advancing Base 1
$92.53 latest close
Market Structure
Trend structure: range
Latest event: bos (bearish)
Inside 92.35–93.01 · 4 touches · moderate
Support 83.93–84.50 · 4 touches · moderate
Support 81.69–81.75 · 3 touches · moderate
Support 72.92–73.38 · 3 touches · moderate
Support 75.92–76.10 · 3 touches · moderate
Join to Watchlist $CVS Share card
Verdict · setup score 68/100 · data Oct 26 close · latest session

Stand aside — setup invalidated

Setup score 68, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart
Recent price action · daily
$90.00$100AugSepOct$92.53

What would change this verdict

What needs to turn for this to become buyable — the top failing checks across the legend council:

  • Minervini 1.4 50-day MA > 150-day MA AND 200-day MA — MA50 $91.52, MA150 $92.32, MA200 $88.58
  • Minervini 1.8 RS rank ≥ 70 (prefer ≥ 85) — RS rank 55
  • O'Neil L: RS rank ≥ 80 (IBD leadership) — RS rank 55
  • O'Neil A: Annual earnings & revenue quality — Rev +7.8% | ROE 3.9%
  • Weinstein Relative strength ≥ 60 — RS 55
  • Weinstein Weekly price coiling (Stage 2 consolidation) — Tightening weekly range confirms base
Minority view — the council disagrees here
  • Minervini: avoid Trend-template read: fails 50-day MA > 150-day MA AND 200-day MA.
  • O'Neil: avoid CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).
  • Weinstein: watch Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.
57 Neutral
Legend Score · rates the stock Neutral (57/100) — held back by eps growth

Our proprietary 0-100 rating — the answer to Wall Street's black-box scores. Five pillars, each computed from real scan data, each explained below in plain English.

  • Relative Strength (25%) 55
  • Trend Template (25%) 75
  • Institutional Footprint (20%) 64
  • EPS Growth (15%) 32
  • Quality (SMR-like) (15%) 44

RS rank 55: middle of the pack — no leadership yet. Trend template 6/8: passes the uptrend screen, structure intact. Institutional score 64: mild accumulation. EPS up +1% — growing, but below the 25% leadership bar. Quality 44: weak fundamentals (sales growth 30, return on equity 40, leverage 100). Updated 2026-10-27.

Earnings

Post-earnings setup

Next earnings Tuesday, October 27, 2026 Before market open Exact clock time not supplied by source

Deterministic evidence

CVS-1.01%
Broad market · SPY+0.71%
Same completed session window ending 2026-10-26. -1.72 points vs SPY.
CatalystUnavailable Stock reactionNegative Sector reactionUnavailable Opening surge— Event riskEarnings-driven

Session internals Weak

Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.

Vs prior close-1.01% From the open-1.25% Range position18% GapNo gap
QQQ confirmationDiverging (+1.11%) SMH confirmationDiverging (+2.74%)
Short-term conviction -1 points.
  • QQQ, SMH moved against the stock — no index confirmation.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $92.53 -1.0% Oct 26 close
52W High $110.68 16.4% below high
Wks Since High 13w
Base Depth 23.1% 23.9% today
RS Rank 17 percentile of scan
SMA 50 $91.52
Avg Vol 7,746,417
Rel Vol (Oct 26) 0.55× 1.32× on up days
More stats
52W Low $69.51
Tight Wks 1
Base B1
SMA 200 $88.58
RS Line vs High -18.2%
RS Line Slope +6.1% ▲
Group Rank #49/66
ADR% 2.3%
ATR(14) $2.35 (2.5%)
Vol Pace (live) N/A
A/D Days 12A / 14D
A/D Rating D
VDU Bars 0/10 d
Earnings TODAY
Position in 52-week range 56thpercentile of the 52-week range
$69.51low
$110.68high

CVS Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for CVS.

Create Free Account

Technical Analysis Report Card

$CVS · $92.53 · as of 2026-10-26 · multi-factor read
68
/ 100
Technicals 68/100
Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating
Weekly ▬ Sideways / consolidating
Monthly ▬ Sideways / consolidating

Moving Averages

50-day$91.52 ↑
100-day$96.90 ↓
200-day$88.58 ↑
Bullish (50 > 200)

RSI (14)

Reading54.6 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateBullish
Histogram+0.760

Bullish — MACD above its signal line and above zero. Histogram contracting.

Bollinger Bands (20,2)

%B / Width72% · 14.8%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol1.32 · Neutral
Rel volume0.55×
Pocket pivots · 10d1
5d vs 50d vol75%
Heavy vol up / down2 / 0

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

  • Pocket pivot 7 sessions ago — up-day volume beat every down day of the prior 10 sessions.
  • 2 heavy-volume up days vs 0 down in the last 20 sessions.

Support & Resistance

R · $98.23swing level
R · $106.15swing level
R · $110.6852-week high
Price · $92.53now
S · $89.42swing level
S · $84.23swing level
S · $74.78swing level

Fibonacci · Downtrend swing

23.6%$90.47
38.2%$94.33
50.0%$97.46
61.8%$100.58
78.6%$105.02

Retracement resistance zones measured from the recent swing high down to the low.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for CVS — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Above 200-day MA50/200 bullish
Want this read in a legend's voice? Ask a Legend about CVS
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
How to read the numbers: the setup score (68/100, in the verdict band) rates this trade setup. Each legend's A–D grade rates the same setup against that legend's own checklist — so a high score next to a C grade is not a contradiction. The setup can be strong without fitting that legend's style. When the council disagrees, the verdict band breaks the tie.

Council consensus: 6 of 9 legends are Watching — building, not yet a confirmed buy.
Minervini Avoid C Trend-template read: fails 50-day MA > 150-day MA AND 200-day MA.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $92.53, MA150 $92.32, MA200 $88.58
1.2 150-day MA > 200-day MAMA150 $92.32 vs MA200 $88.58
Failing evidence
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $91.52, MA150 $92.32, MA200 $88.58
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 55
6/10 checks
Method → Playbook → Ask →
O'Neil Avoid D CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).
Passing evidence
C: Quarterly EPS acceleration ≥ 25%+135.8% QoQ
S: Base tightness (ATR% ≤ 4.5%)ATR% 2.54%
Failing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 55
A: Annual earnings & revenue qualityRev +7.8% | ROE 3.9%
2/8 checks
Method → Playbook → Ask →
Weinstein Watch C Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.

mediumClassic Stage 2 advancing phase — strong weekly trend confirms uptrend. This is Weinstein's sweet spot: buy and hold while price remains above the 30-week MA.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $92.53 vs MA200 $88.58
Failing evidence
Relative strength ≥ 60RS 55
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
4/7 checks
Method → Playbook → Ask →
dennis Watch C Turtle read: no breakout yet. Price is pressing the 20-day high. The system waits for the print; it never anticipates.
Passing evidence
No breakdown below the 20-day channel20-day low $84.23
Volatility-unit sizing (1N ≈ 1% of equity)1N = $2.23 (2.41% of price); the Turtles size 1 unit so a 1N move ≈ 1% of equity, making the 2N stop ≈ 2% equity risk
Failing evidence
S1: 20-day Donchian breakoutNot confirmed
S2: 55-day Donchian breakoutNot confirmed
5/7 checks
Method → Playbook → Ask →
zanger Avoid D Zanger read: a hard gate is broken — either the pattern is not one of his six, or the entry is more than 5% past the breakout. He would not touch this.
Passing evidence
Partial-profit plan: sell 20-30% at +15-20%Scale 20-30% at $106.41-$111.04; trail the rest
Trail on the 10/20-day MA10-day MA $92.42 · 20-day MA $89.59 — exit the remainder on a close below the trail
Failing evidence
Named Zanger pattern onlyTrend Only is not one of Zanger's six
Not extended (≤5% above the breakout point)Data unavailable
3/6 checks
Method → Playbook → Ask →
zweig Watch D Zweig read: part of his screen passes but not all: Reasonable price for the growth (P/E ≤ 35); Insider buying; Price strength (RS ≥ 70) — wait for the full growth screen before treating this as a Zweig setup.
Passing evidence
EPS growth above the market (≥15% QoQ)+135.8% QoQ — Zweig wants growth above the S&P average
Breadth momentum: 10-day A/D ratio10-day A/D 1.17 (1995 adv / 1699 dec) — participation expanding
Failing evidence
Reasonable price for the growth (P/E ≤ 35)Trailing P/E 66.6x — no PEG or forward P/E stored
Insider buyingNo insider buying flagged
3/8 checks
Method → Playbook → Ask →
Livermore Watch B Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$92.53
Distance from 52-week high16.4% below high
Failing evidence
Relative strengthRS 55
Volume vs average0.55x
3/6 checks
Method → Playbook → Ask →
Darvas Watch B Box-theory read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$92.53
Distance from 52-week high16.4% below high
Failing evidence
Relative strengthRS 55
Volume vs average0.55x
3/6 checks
Method → Playbook → Ask →
Wyckoff Watch B Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$92.53
Distance from 52-week high16.4% below high
Failing evidence
Relative strengthRS 55
Volume vs average0.55x
3/6 checks
Method → Playbook → Ask →
Base & Breakout
Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking
RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
100RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -4 D
A: 12 D: 16 Net: -465 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met
C 3/7 criteria
Separate score from the Minervini Trend Template (6/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✓ EPS acceleration ≥25% QoQ +136%
✗ Revenue growth ≥20% YoY +8%
✗ Gross margin ≥30% 14%
✗ ROE ≥17% 4%
✗ RS rating ≥80 (leadership) 55
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -16.4%

Method Playbook

Trade it like O'Neil EXACT LEVELS · PRO
O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro level
Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

Pattern Analysis

Trend Only
68 setup score
RS Score 55
Trend template 6/8
Why This Setup?
The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met
  • A relative-strength leader — not met RS rank 17 — laggard
  • Clear of earnings — not met in 0 days — event risk
  • Risk is defined — not met No stop — undefined risk
  • Asymmetric reward — partly met No target set
  • Not chasing (in range) — partly met Pivot distance unknown
  • Volume confirms — partly met 0.6× average — light
  • In a confirmed uptrend — met Stage 2 · Trend template 6/8
Why these seven? → The Universal Edge

Minervini Trend Template

6/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $92.53 vs SMA150 $92.32 / SMA200 $88.58
SMA 150 above SMA 200 SMA150 $92.32 vs SMA200 $88.58
SMA 200 trending up Slope +1.03 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $91.52
Price above SMA 50 $92.53 vs SMA50 $91.52
30%+ above 52-week low +33.1% from $69.51
Within 25% of 52-week high -16.4% from $110.68
RS score above 70 RS 55

Fundamentals

52W Range
56%
Mkt Cap SEC
118.3B
EPS QoQ
+136%
Rev YoY
+8%
ROE
4%
Gross Margin
14%
D/E
0.86
EPS TTM
$1.39
P/E TTM
66.6x
Float
1.3B
Insider
No Buy

Company

Company profile
CVS Health Corporation
CVS · NYSE · Retail Trade · Drugstore Chains
Track all markets on TradingView

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
6/8
W. RS
59
W. Support
$77.61
W. Resist
$110.68
Weekly Structure

Scan History

20× streak
Oct 23: 67 (Trend Only)Oct 23: 68 (Trend Only)Oct 26: 66 (Trend Only)Oct 26: 66 (Trend Only)Oct 27: 68 (Trend Only)68
Oct 27
Trend Only ✓ Gate
68
Oct 26
Trend Only ✓ Gate
66 0.0%
Oct 26
Trend Only ✓ Gate
66 0.0%
Oct 23
Trend Only ✓ Gate
68 -1.0%
Oct 23
Trend Only ✓ Gate
67 -1.0%

Latest News

Headlines for CVS
Loading headlines…

Get the full picture on CVS

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial